[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368510-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368510-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ykl-40-and-risk-of-incident-cancer-in-early-type-2-diabetes-a-danish-cohort-study","YKL-40 and risk of incident cancer in early type 2 diabetes: a Danish cohort study","","Association of serum YKL-40, an inflammatory biomarker, with incident cancer risk in early type 2 diabetes is assessed in a Danish cohort. 11,346 newly diagnosed participants were followed for up to 14 years. YKL-40 levels were analyzed in five percentiles and continuously against cancer outcomes, using Cox regression. Compared with the lowest YKL-40 category, elevated levels predicted obesity-related, gastrointestinal, liver, and bladder cancers, while other cancers showed no association. YKL-40 and CRP differed in prognostic performance across cancer sites.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ykl-40-and-risk-of-incident-cancer-in-early-type-2-diabetes-a-danish-cohort-study/368510/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ykl-40-and-risk-of-incident-cancer-in-early-type-2-diabetes-a-danish-cohort-study/368510.png","ImageObject",300,407,{"name":42,"@type":43},"Riley West","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of this study?","Question",{"text":63,"@type":64},"To examine whether serum YKL-40 is associated with the risk of incident cancer in individuals with early type 2 diabetes, and to compare its prognostic performance with CRP.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was YKL-40 measured and analyzed?",{"text":68,"@type":64},"YKL-40 was categorized into five percentiles and also analyzed continuously using Cox regression models.",{"name":70,"@type":61,"acceptedAnswer":71},"Which cancers showed an association with higher YKL-40?",{"text":72,"@type":64},"Higher YKL-40 predicted obesity-related, gastrointestinal, liver, and bladder cancers, while no associations were found for the other cancer types assessed.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368510,1790756969,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","British Journal of Cancer [www.nature.com/bjc](www.nature.com/bjc)  \nARTICLE OPEN   \nEpidemiology  \nYKL-40 and risk of incident cancer in early type 2 diabetes: a Danish cohort study  \nAlisa D. Kjaergaard 1 ✉ , Allan A. Vaag2,3, Verena H. Jensen2, Michael H. Olsen4, Kurt Højlund5, Peter Vestergaard6, Torben Hansen7, Reimar W. Thomsen8,9 and Niels Jessen 1,9  \n© The Author(s) 2025  \n\n|  | BACKGROUND: We examined the association of serum YKL-40, an inﬂammatory biomarker, with incident cancer risk in early type 2 diabetes.\u003Cbr>METHODS: A cohort of 11,346 individuals newly diagnosed with type 2 diabetes was followed for up to 14 years. YKL-40 levels (n = 9010) were categorised into ﬁve percentiles (0–33%, 34–66%, 67–90%, 91–95%, and 96–100%), and baseline YKL-40 and CRP (n = 9644) were analyzed continuously (per 1 SD log increment) for comparison. Cox regression models assessed associations with obesity-related, gastrointestinal, liver, pancreatic, colorectal, bladder and lung cancers, as well as cancers of reproductive organs. RESULTS: Adjusted HRs (95% CIs) for the highest versus lowest YKL-40 category were 2.4 (1.6–3.7) for obesity-related, 2.6 (1.7–4.1) for gastrointestinal, 44.2 (12.8–153.4) for liver, and 4.2 (1.3–14.1) for bladder cancers. No associations were found for other cancers. YKL-40 and CRP had similar prognostic abilities for obesity-related and gastrointestinal cancers, but YKL-40 outperformed CRP for liver and bladder cancers. Conversely, CRP was a stronger predictor for lung, colorectal, and ovarian cancers.\u003Cbr>DISCUSSION: YKL-40 was associated with the risks of liver and bladder cancers, clearly outperforming CRP for these cancers This |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| .\u003Cbr>suggests distinct prognostic roles for YKL-40 and CRP, and highlights YKL-40 as a promising biomarker for liver cancer. |  |  |\n|  | British Journal of Cancer (2025) 132:1019–1026; [https://doi.org/10.1038/s41416-025-02996-5](https://doi.org/10.1038/s41416-025-02996-5) |  |\n|  |  |  |\n\nINTRODUCTION  \nYKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is an inﬂammatory biomarker produced locally at inﬂammation sites by cells such as tumour-associated macrophages and cancer cells [1] . Consequently, YKL-40 is elevated in many cancers, including liver, colorectal, and lung cancers, where it contributes to tumour progression by promoting growth, inﬂammation, immune evasion and metastasis [1, 2] . Consistent with this, inhibiting YKL-40 has been shown to effectively reduce tumour growth in these cancers [3–6] .  \nMoreover, YKL-40 levels are consistently higher in individuals with type 2 diabetes compared to healthy controls [7, 8] . Given that obesity is a major modiﬁable risk factor for type 2 diabetes, there is a substantial overlap between the cancers associated with obesity (gastrointestinal, thyroid, and kidney cancers, multiple myeloma, meningioma, and breast, ovarian, and endometrial cancers) and those linked to type 2 diabetes [9, 10] . A metaanalysis of 32 million individuals found that type 2 diabetes is associated with increased risks of gastrointestinal (especially liver  \nand pancreatic), thyroid, kidney, and bladder cancers, as well as breast, ovarian, and endometrial cancers in women, and a reduced risk of prostate cancer in men [9] . This overlap may arise from shared mechanisms, such as insulin resistance and chronic inﬂammation, that promote tumour development [11] .  \nProspective studies examining cancer risk have previously been conducted in the Danish general population, with cohorts including 8706 to 21,643 adults in the Greater Copenhagen area. These studies have shown that elevated YKL-40 is associated with an increased risk of developing gastrointestinal and possibly lung cancer, but not with breast, prostate, or other cancers [2, 12, 13] .  \nHowever, to our knowledge, no prospective studies have ever speciﬁcally","cbCaiprDnuBSMLvJ","https://ap.wps.com/l/cbCaiprDnuBSMLvJ","pdf",471013,"English","# Background\n# Methods\n## Study cohort\n# Results\n# Discussion\n# Introduction","[{\"question\":\"What is the main objective of this study?\",\"answer\":\"To examine whether serum YKL-40 is associated with the risk of incident cancer in individuals with early type 2 diabetes, and to compare its prognostic performance with CRP.\"},{\"question\":\"How was YKL-40 measured and analyzed?\",\"answer\":\"YKL-40 was categorized into five percentiles and also analyzed continuously using Cox regression models.\"},{\"question\":\"Which cancers showed an association with higher YKL-40?\",\"answer\":\"Higher YKL-40 predicted obesity-related, gastrointestinal, liver, and bladder cancers, while no associations were found for the other cancer types assessed.\"}]","YKL-40 and risk of incident cancer in early type 2 diabetes: a Danish cohort study | PDF",1790177297,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe344f86f3f085a7ef78e2d7145a664f.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a0aa503e2b9ffe799d075042acdca05.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5bac53a952e04c59db918290b821ed5e.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62c4e8f41fb4cb505fa23416a8c8499b.webp",980,1301]